Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects.
Ibopamine is a dopamine-like drug that shows mainly vasoactive properties, predominantly acting on dopamine1-(DA1-) and DA2-adrenoceptors. Ibopamine increases cardiac output, reduces peripheral vascular resistance, and increases renal blood flow, exerting a lesser effect on preload parameters. This hemodynamic improvement is also present even after relatively long-term treatment. There is no evidence of pharmacologic tolerance. In relation to DA2-activation, ibopamine modulates the neurohumoral consequences of heart failure with decreases in plasma renin activity and aldosterone and norepinephrine plasma levels, an effect that can be beneficial in the long-term treatment of heart failure patients.
Servico de Coronariopatias, Hospital La Paz, Madrid, Spain.
J
J
López-Sendón
D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D018377:Neurotransmitter Agents; D014665:Vasodilator Agents / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D015259:Dopamine Agents; D018377:Neurotransmitter Agents; D014665:Vasodilator Agents; C023487:ibopamine; D003846:Deoxyepinephrine